GlassScriptPhysician profile
Danielle M Levine
NPI 1194037408
$7,100.34
in general payments reported to CMS, 2019-2025
35 companies · $1,377 in 2025
The $1,377 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $481 · 2021: $708 · 2022: $1,535 · 2023: $962 · 2024: $1,095 · 2025: $1,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,195 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,194.71 |
| Education | $239.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,490.67 | 2019-2025 | |
| Genzyme Corporation | $828.65 | 2019-2025 | |
| Janssen Biotech, INC. | $776.63 | 2019-2024 | Tremfya, Stelara, Simponi |
| Novartis Pharmaceuticals Corporation | $703.23 | 2019-2025 | |
| Pfizer INC. | $437.61 | 2019-2024 | |
| Sun Pharmaceutical Industries INC. | $323.63 | 2022-2025 | Ilumya, Winlevi |
| Galderma Laboratories, L.P. | $273.89 | 2019-2025 | Nemluvio |
| E.R. Squibb & Sons, L.L.C. | $270.05 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $246.59 | 2022-2025 | Adbry, Anzupgo |
| Allergan, INC. | $208.06 | 2019-2022 | |
| Incyte Corporation | $184.43 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $179.50 | 2019-2025 | Taltz, Ebglyss |
| Kerecis Limited | $125.04 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Regeneron Healthcare Solutions, INC. | $111.46 | 2019-2025 | Dupixent |
| Boston Scientific Corporation | $110.61 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $100.28 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $90.93 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $89.99 | 2025 | |
| Arcutis Biotherapeutics, INC. | $75.70 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $70.43 | 2020-2021 | |
| Botanix Sb INC | $52.35 | 2025 | Sofdra |
| Merz North America, INC. | $49.80 | 2021-2022 | |
| Ucb, INC. | $38.59 | 2023-2025 | Bimzelx, Cimzia |
| Organogenesis INC. | $35.33 | 2025 | Novachor |
| Merck Sharp & Dohme LLC | $34.58 | 2019 | |
| Convatec INC. | $29.14 | 2025 | |
| Biofrontera INC. | $29.05 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Amgen INC. | $22.59 | 2025 | Otezla |
| Smith+Nephew, INC. | $21.07 | 2025 | Collagenase Santyl |
| Verrica Pharmaceuticals INC. | $18.06 | 2023 | Ycanth |
| Mission Pharmacal Company | $17.06 | 2019 | |
| Almirall LLC | $16.23 | 2024 | Seysara |
| Dermavant Sciences, INC. | $14.25 | 2023 | Vtama |
| Dermira, INC. | $12.77 | 2020 | |
| Genentech USA, INC. | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.